Phaseline

Companies › Ascendis Pharma Endocrinology Division

Ascendis Pharma Endocrinology Division: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lonapegsomatropin
Growth hormone receptor agonist
GHRPhase 2Turner SyndromeDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05690386LonapegsomatropinPhase 2Turner SyndromeOtherDec 2027

Targets

GHR (1)

Companies with the same targets

Novo Nordisk Changchun GeneScience Pharmaceutical Ascendis Pharma Growth Disorders Ascendis Pharma

Companies built like this

Ascendis Pharma Growth Disorders Eirion Therapeutics Airway Therapeutics Inotrem Tego Science

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.